ALX Oncology
ALXO
87 hedge funds and large institutions have $69M invested in ALX Oncology in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 26 closing their positions.
124% more call options, than puts
Call options by funds: $427K | Put options by funds: $191K
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 92 → 87 (-5)
8.44% less ownership
Funds ownership: 86.31% → 77.87% (-8.4%)
17% less capital invested
Capital invested by funds: $83.1M → $69M (-$14.2M)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.35M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
+$1.88M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.32M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.27M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.34M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.17M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.57M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.4M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$540K |
ALXO Hedge Fund Activity: Q4 2024 in Review
87 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2024, worth a combined $69M — down 17% from $83.1M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ALXO and 21 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 32 added.
The largest buyer was Morgan Stanley, adding an estimated $3.35M. The largest seller was Vivo Capital, exiting entirely with an estimated $7.34M sold.
- 87 institutional investors held ALX Oncology (ALXO) as of Q4 2024, down from 92 in Q3 2024.
- Funds reported $69M of ALX Oncology stock for Q4 2024, down 17% quarter-over-quarter.
- 21 funds opened new ALX Oncology positions in Q4 2024 and 26 closed out, a net change of -5 holders.
- The largest ALX Oncology buyer in Q4 2024 was Morgan Stanley, an estimated $3.35M added.
- The largest ALX Oncology seller in Q4 2024 was Vivo Capital, an estimated $7.34M sold.
Based on aggregated 13F filings for Q4 2024.